Healthcare

HR 3492, the Protect Children’s Innocence Act, makes it a federal crime to perform genital or bodily mutilation or chemical castration on minors under 18, except for specific medical reasons. The bill broadly defines prohibited procedures to include gender transition-related surgeries (like hysterectomies or mastectomies) and medical treatments such as puberty blockers or cross-sex hormones administered to minors. It criminalizes these acts when they occur across state lines, involve payments, or use interstate commerce, while explicitly banning religious tradition as a defense. Exceptions include medically necessary procedures for health emergencies, childbirth, or conditions certified by a physician.

HR 498, the "Do No Harm in Medicaid Act," prohibits federal Medicaid funding for gender transition procedures for individuals under 18 years old. The bill amends the Social Security Act to define "specified gender transition procedures" broadly, including surgeries, hormone treatments, and certain medications, and bans federal Medicaid coverage for these services for minors. Exceptions are made only for medically necessary treatments related to precocious puberty, genetic disorders of sex development, or urgent medical conditions requiring bodily correction (like infections or injuries from prior procedures). This directly affects minors enrolled in Medicaid state plans, as states would no longer receive federal funds for these specific covered services.

Halt All Lethal Trafficking of Fentanyl Act or the HALT Fentanyl Act This act permanently places fentanyl-related substances as a class into schedule I of the Controlled Substances Act. A schedule I controlled substance is a drug, substance, or chemical that has a high potential for abuse; has no currently accepted medical value; and is subject to regulatory controls and administrative, civil, and criminal penalties under the Controlled Substances Act. Under the act, offenses involving fentanyl-related substances are triggered by the same quantity thresholds and subject to the same penalties as offenses involving fentanyl analogues (e.g., offenses involving 100 grams or more trigger a 10-year mandatory minimum prison term). Additionally, the act establishes a new, alternative registration process for certain schedule I research. The act also makes several other changes to registration requirements for conducting research with controlled substances, including permitting a single registration for related research sites in certain circumstances, waiving the requirement for a new inspection in certain situations, and allowing a registered researcher to perform certain manufacturing activities with small quantities of a substance without obtaining a manufacturing registration. Finally, the act expresses the sense that Congress agrees with the interpretation of the Controlled Substances Act in United States v. McCray , a 2018 case decided by the U.S. District Court for the Western District of New York. In that case, the court held that butyryl fentanyl, a controlled substance, can be considered an analogue of fentanyl even though, under the Controlled Substances Act, the term controlled substance analogue specifically excludes a controlled substance.